25
Justice in Health Care: NICE & Alzheimer’s Disease Dr Colin Mitchell MSc Geriatric Medicine – Ethics & Law

NICE & Alzheimer's Drugs

Embed Size (px)

Citation preview

Page 1: NICE & Alzheimer's Drugs

Justice in Health Care:NICE & Alzheimer’s Disease

Dr Colin MitchellMSc Geriatric Medicine – Ethics & Law

Page 2: NICE & Alzheimer's Drugs

Objectives

Case – A patient with mild Alzheimer’s disease Review NICE’s decision process relating to Alzheimer’s drugs Examine recent High /Appeal Court judgments on this process Review legal precedents in health resource allocation Discuss the ethical underpinnings of distributive justice Examine how these influence practical healthcare rationing Assess NICE’s role in health resource allocation

Page 3: NICE & Alzheimer's Drugs

Clinical Case

74yr old man, referred with ‘funny turns’ Wife gives history of dizzy spells on standing Mild postural drop, probably related to BFZ Main issue for wife – husband’s failing memory MMSE: 23/30 Bloods / CTB – NAD Referred to Memory Clinic

Page 4: NICE & Alzheimer's Drugs

Drug Treatment for Alzheimer’s

Cholinesterase inhibitors (CE-Is) Donepizil, Galantamine, Rivastigmine, (Memantine) Trials show benefit for patients with MMSE 10-26

NICE (Guideline 42, 2006) Donepizil, Galantamine, Rivastigmine for

Alzheimer’s Dementia of moderate severity MMSE 10-20

Olden M & Kelly C, 2002. Use of cholinesterase inhibitors in Dementia. Advances in Psychiatric Treatment 8:89-96

Page 5: NICE & Alzheimer's Drugs

NICE – Background

Set up in 1999 to provide 3 main services to the NHS Appraisal of health technology Clinical guidelines Advice on safety and effectiveness of procedures

NICE ‘constitution’ Comprehensive, evidence-based, fair, transparent Right to appeal

Topics chosen by DoH

DoH, 2005. Directions and Consolidating Directions to the National Institute for Health and Clinical Excellence

Page 6: NICE & Alzheimer's Drugs

NICE and CEIs – Timeline

2003 – CE-I review begins

June 2005 – Final Appraisal Determination Recommends no CE-Is to be available on the NHS Unusually, NICE Guidance executive postpone final publication

pending new data

May 2006 – Final Appraisal Document Approved for Mod. Alzheimer’s disease (10-20) This excludes around 60% of Alzhimer’s patients

Page 7: NICE & Alzheimer's Drugs

LAW

Page 8: NICE & Alzheimer's Drugs

NICE and CEIs

Decision appealed by interest groups Nov 2006 – Appeals rejected, guidance issued 2007 – Proceeds to Judicial Review

1. Procedural unfairness

2. Perversity in light of evidence submitted

Page 9: NICE & Alzheimer's Drugs

R (Eisai Ltd) v NICE [2007]

Arguments submitted to Dobbs J: Procedurally unfair (read-only Excel spreadsheet) Irrationality

Too much weight on one, flawed, trial Cumulative / Long term benefits not taken into account Care costs not correctly weighted Out-of-date care costs used

Failure to show consideration to statutory duties under race relations act (1976) and disability discrimination act (1995)

Eisai Ltd v NICE [2007] EWHC 1941 (Admin)Syrett K, 2008. “Nice and Judicial Review: Enforcing Accountability for Reasonableness through the Courts?” Medical Law Review 16:127-140

Page 10: NICE & Alzheimer's Drugs

R (Eisai Ltd) v NICE [2007]

Arguments submitted to Dobbs J: Procedurally unfair (read-only Excel spreadsheet) Irrationality

Too much weight on one, flawed, trial Cumulative / Long term benefits not taken into account Care costs not correctly weighted Out-of-date care costs used

Failure to show consideration to statutory duties under race relations act (1976) and disability discrimination act (1995)

Eisai Ltd v NICE [2007] EWHC 1941 (Admin)Syrett K, 2008. “Nice and Judicial Review: Enforcing Accountability for Reasonableness through the Courts?” Medical Law Review 16:127-140

Page 11: NICE & Alzheimer's Drugs

Dobbs J, 2007

“It is important to stress that this is not… a challenge to a decision by NICE… Nor is it… a case of the claimant asking the court to rule that NICE recommend treatment… for mild Alzheimer’s disease sufferers. It is also not about the court to decide whether an Alzheimer’s disease sufferer is worth £2.50 a day”

Page 12: NICE & Alzheimer's Drugs

NICE and CE-Is (cont)

Sept 2007 – Revised guidance issued by NICE Changed guidance relating to learning difficulties / language NICE claims its position has been vindicated

Appeal decision in May 2008…

Page 13: NICE & Alzheimer's Drugs

Appeal Court 2008

Justices Richards, Tuckey and Jacob disagree with Dobbs J on the question of procedural unfairness (the ‘read-only model’) “The robustness or reliability of the model is… a key question” “[the] remarkable degree of disclosure and of transparency in the

consultation process… cuts both ways, because it also serves to underline the… importance of the exercise”

The Lords denies NICE the right to appeal in Oct 2008

R (Eisai Ltd) v NICE [2008] EWCA Civ 438

Page 14: NICE & Alzheimer's Drugs

Challenges to Allocation Decisions

R v Central Birmingham Health Authority, ex P Collier (1988) HA repeatedly cancelled necessary paediatric cardiac surgery Court refused to order the surgery be carried out immediately

R v Cambridge District Health Authority, Ex P B (1995) HA refused to fund experimental chemotherapy Laws J ordered the HA to reconsider:

HA must do more than ‘merely toll the bell of tight resources’ Court of Appeal rejects Laws J’s judgment:

‘Agonising judgements have to be made as to how a limited budget is best allocated… That is not a judgement which the court can make’

Page 15: NICE & Alzheimer's Drugs

Challenges to Allocation Decisions

R v North Derbyshire Health Authority (1997) NDHA refused to fund B-interferon in MS HA found to have failed to take a reasoned decision about

the provision of B-interferon, by ignoring DoH advice and not individually assessing patients’ needs.

R v Swindon NHS PCT (2006) Herceptin unlicensed for early-stage CA Breast Court of Appeal decides that the PCT’s blanket refusal policy

was irrational and unlawful

Page 16: NICE & Alzheimer's Drugs

Health Resources – The Court’s Role

Eisai v NICE is the only legal challenge so far to NICE Actual effects on guidance are limited (so far)

Appraisal process more transparent Rulings may increase complexity of process and time taken to

produce recommendations

Courts seem reluctant to become activist in making judgments on resource allocation decisions

However it is clear that the decision process must be both thorough and transparent.

Page 17: NICE & Alzheimer's Drugs

ETHICS

Page 18: NICE & Alzheimer's Drugs

Justice v Beneficence

How can we reconcile our requirement to do the best for our patient with the need to do the best for ALL patients?

With finite resources, you can’t have all 3 of: Comprehensive care Best quality care Care based on need rather than ability to pay

Therefore healthcare must be rationed But we pretend it’s not being rationed (Covert rationing)

Weale A, 1998. “Rationing Healthcare” – BMJ Vol.316

Page 19: NICE & Alzheimer's Drugs

Justice

Aristotle’s (circa 350BC) formal principle of justice is widely accepted: Justice is not equal division of benefit / burden Equals should be treated equally and unequals unequally in

proportion to the relevant inequalities Fair and proportionate treatment – ‘Just desserts’ How to assess proportionality?

Aristotle. Nicomachean Ethics. Translated by Crisp R, 2000, Cambridge University Press

Page 20: NICE & Alzheimer's Drugs

Traditional Theories of Justice

Libertarianism Stresses autonomy, right to life and property

Marxism To each according to his needs, from each according to his ability

Utilitarianism Welfare maximisation at the expense of autonomy

Page 21: NICE & Alzheimer's Drugs

A Theory of Justice

John Rawls’ Theory of Justice Renders impartiality through ‘veil of ignorance’ Result is two principles:

1. Maximal liberty compatible with same degree of liberty for everyone

2. Deliberate inequalities are unjust unless they work to the advantage of the least well off

Blending of utilitarianism and respect for autonomy

Rawls J, 1971 “A Theory of Justice”

Page 22: NICE & Alzheimer's Drugs

NICE’s role in distributive justice

Rationing must be thoroughly, fairly and transparently assessed

NICE is THE model of fair / transparent healthcare assessment

However its role in distributive justice is limited Only assesses a small proportion of healthcare QALY is a crude tool Problems with disinvestment Targeted towards expensive / controversial treatments Prone to political / interest-group pressure Technical experts not suited to a role making value judgments

about the nature and purpose of the NHS

Hill S et al, 2003 “Technology Appraisal Programme of NICE: Review by WHO”

Page 23: NICE & Alzheimer's Drugs

NICE’s role in distributive justice

Rationing must be thoroughly, fairly and transparently assessed

NICE is THE model of fair / transparent healthcare assessment

However its role in distributive justice is limited Only assesses a small proportion of healthcare QALY is a crude tool Problems with disinvestment Targeted towards expensive / controversial treatments Prone to political / interest-group pressure Technical experts not suited to a role making value judgments

about the nature and purpose of the NHS

Hill S et al, 2003 “Technology Appraisal Programme of NICE: Review by WHO”

Page 24: NICE & Alzheimer's Drugs

Conclusions

NICE’s decision on funding CE-Is for Alzheimer’s disease has thrown up new questions about its role and processes

Courts have traditionally been reluctant to challenge health resource allocation decisions

Eisai v NICE has been heralded as a landmark decision, but results in only a small change in NICE’s deliberative and appeal processes

Page 25: NICE & Alzheimer's Drugs

Conclusions (2)

NICE, while a remarkably high-quality institution, is not the solution to the difficulties of fairly allocating health resources The question of distributive justice is far bigger than NICE, and the

courts are even less able to intervene. Healthcare rationing is an ethical and political issue, more than

purely a legal, technical or medical one.

So far, little substantive debate outside of specialized settings So covert rationing continues and healthcare is unfairly distributed And my patient does not receive donepizil